Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.

Abstract: Certain azapirone compounds and their pharmaceutically acceptable salts are useful in the treatment of substance addiction.

Abstract: A composition is provided for use in the suppression of a smoking habit, containing a tobacco plant extract which includes between 0.1% and 8.0% of nicotine and at least one additional tobacco derivative in a water based solvent. A process for producing the extract is also provided.

Abstract: The administration to a poly-drug addict of ibogaine, ibogaine, tabernanthine, alkaloids in the family of apocynaceae, or their non-toxic salts have been discovered to interrupt the physiological and psychological aspects of poly-drug dependency (heroin, cocaine, alcohol, nicotine, caffeine, amphetamine, desoxyephedrine or methadone in combinations thereof). A single treatment or series of treatments may be effective for one to eighteen months or longer. Treatment consists of the oral or rectal administration of ibogaine, ibogamine, tabernanthine or their salts or derivatives in dosage ranges of 1 mg/kg to 60 mg/kg.

Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

Abstract: A method for smoking cessation therapy is described that utilizes transdermal nicotine delivery for obtaining base-line coupled with buccal administration of nicotine to satisfy transient craving.

Abstract: An anti-smoking remedy with biochemical effect. The remedy consists of non-toxic plant components including Radix bupleuri, Radix peucedani and Rhizoma cimicifugae. Additional components to the preparation can include Rhizome phragmiles, or a mixture of Pinellia ternata and either Liguiritiae or Robinia pseudo acacia.

Abstract: An antismoke mouthwash comprising silver nitrate and propylene glycol in water, a process for preparing said mouthwash and a method of using the mouthwash to help a smoker quit smoking.

Abstract: A method for eliminating an individual's tobacco smoking habit and associated nicotine dependence includes the step of gradually decreasing tobacco consumption over a first period of time until no further tobacco is consumed. This is done by first recording the individual's daily tobacco consumption. The day is broken down into consumption periods of one hour each. An alternative oral nicotine source is then progressively administered as a substitute for tobacco consumed during sequential consumption periods over each succeeding day for approximately two weeks until no further tobacco is consumed. Following a period during which the administration of the alternative nicotine source is maintained, it, too, is progressively eliminated over a period of approximately sixteen weeks.

Abstract: Methods and compositions are provided for treating drug-dependent individuals so as to effect withdrawal from the drug of abuse, e.g., natural and synthetic narcotics, or stimulant-type drugs such as cocaine, amphetamines, nicotine, or the like. The method involves substitution therapy wherein a serotonin antagonist such as ergotamine or a derivative thereof and a CNS stimulant such as caffeine are substituted for the drug of abuse.

Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.

Abstract: A mouthwash is disclosed and claimed which comprises silver acetate, ammonium nitrate, and nitric acid which, when present as a residue in the oral cavity, will cause an adverse taste when the user smokes a tobacco product. The bitter taste experience causes the development of an aversion to smoking. The use of other non-toxic silver compounds is also disclosed.

Abstract: Individuals are aided in smoking cessation by administering internally phenylpropanolamine.

Abstract: Compositions useful in the treatment of disturbances of appetite, disturbances of mood, or both, nicotine withdrawal associated as well as experienced by individuals after discontinuing tobacco use as methods of use therefor. The compositions include serotoninergic drugs, such as d-fenfluramine and fluoxetine.

Abstract: Anti-smoking oral preparations are provided containing a silver compound as the anti-smoking agent and a sweetener in which the silver compound is present in amounts of from 0.1 mg. to 2.5 mg. and the ratio of sweetness intensity based on sucrose to silver compound content is from 100:1 to 2500:1.

Abstract: A method of treating people to stop smoking comprising the steps of brewing strong tea in an open container, partly immersing a plurality of cigarettes into the tea for 4 to 8 hours until the tea is absorbed into the cigarettes throughout their length and staining the cigarettes to a dark brown color, placing the container in an enclosed room in an atmosphere of vaporized camphor crystals for a limited period, breathing the camphorized atmosphere while visually concentrating upon the appearance of the cigarettes in the container and smelling the exuded nicotine and caffeine aroma from the container for a period of about 20 minutes, and psychologically reacting to the appearance of the cigarettes and the aroma of the caffeine and nicotine in a lung-cleansing camphor atmosphere, the user losing all interest in smoking another cigarette.

Abstract: The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.

Abstract: A preparation for the once-daily, percutaneous administration of nicotine comprises nicotine uniformly distributed in a solid, semi-solid or mucilaginous medium which can be placed in intimate contact with the skin, the solid, semi-solid or mucilaginous medium is formed by adding a given amount of nicotine to a solution of a solidifying or gel-forming agent or mixture thereon in a suitable solvent or mixture of solvents and mixing or heating the mixture thereby obtained so as to form the solid, semi-solid or mucilaginous medium.The preparation can be used in a method of treating withdrawal symptoms associated with smoking cessation and for combating the psychological dependence that occurs through frequency smoking.

Abstract: A therapeutic method for treatment of nicotine withdrawal syndrome symptoms of a patient in need thereof by administering to the patient a therapeutic composition of a pharmaceutically acceptable carrier and fluoxetine in an amount effective to provide physiological relief from the withdrawal symptoms.

Abstract: The present invention provides 1-phenyl-(naphthalenyl)alkylamines which are selective inhibitors of serotonin uptake.

Abstract: A method of treating warm-blooded animals to reduce their dependency upon nicotine comprising administering to such animals a medicament containing a 2-pyrimidinyl-1-piperazine derivative of the formula ##STR1## in which n stands for 2, 3, 4, 5 or 6 and R stands for ##STR2##

Abstract: The invention relates to the use of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one and physiologically acceptable salts and solvates thereof in the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse.

Abstract: Anti-smoking oral preparations are provided containing a silver compound as the anti-smoking agent and a sweetener in which the silver compound is present in amounts of from 0.1 mg. to 2.5 mg. and the ratio of sweetness intensity based on sucrose to silver compound content is from 100:1 to 2500:1.

Abstract: The control of tobacco use in humans with a direct dopamine receptor agonist.

Abstract: Administering divided dose of oral Clonidine potentiated by an intramuscular tricyclic antidepressant alleviates the abstinence syndrome resulting from withdrawal of nicotine by smoking cessation. Patient response to the Clonidine/tricyclic serves as the basis for titrating the dosages of transdermal Clonidine and oral buspar administered daily for two weeks following the office visit. Behavioral counseling, supported by written and audio materials on diet, nutrition, exercise, stress management, and habit control, are provided to the patient. Following up support groups are also made available.

Abstract: A method for the treatment of the craving for nicotine in nicotine withdrawal syndrome comprising administering to the patient a composition including glucose or a sugar convertable to glucose in the body of the patient, potassium in ionic form (K+) or a potassium compound capable of dissociating in vivo to release potassium ions, and caffeine or a xanthine equivalent to caffeine in its capacity to elevate the metabolic rate, the glucose and potassium being present in an amount to quickly restore the levels of blood glucose and potassium in the patient to that which his body has become accustomed as a result of repeated nicotine stimulation, caffeine being present in an amount to stimulate metabolism and mental alertness to which his central nervous system has become accustomed by repeated nicotine stimulation.

Abstract: In human subjects accustomed to smoking tobacco the withdrawal symptoms associated with the cessation or reduction of tobacco smoking may be prevented by administering to the subject an effective amount of an alpha-2 adrenergic agonist such as clonidine hydrochloride for a suitable period of time.Alternatively, such withdrawal symptoms may be prevented by administering to such a person an effective amount of alprazolam.

Abstract: A method of treatment to reduce or eliminate the symptoms of smoking withdrawal syndrome in tobacco smokers comprising the administration of at least one dose of a corticotrophin or a corticotrophin analog.

Abstract: Percutaneous administration of nicotine in a dose approximating the dose delivered by a variety of nicotine-containing products, such as cigarettes, cigars, snuff and chewing tobacco, is carried out using an occlusive pad. The nicotine is delivered so as to mimic the pharmacological effects of nicotine provided by the conventional use of tobacco, and a therapeutic function is achieved by reducing or eliminating the need for the tobacco product. A suitable transdermal application pad comprises a reservoir for liquid nicotine base to be affixed to the skin in a variety of places. Due to the high lipid solubility and resultant high skin permeability of nicotine, vehicles or solvents are not generally needed to enhance dermal absorption.

Abstract: A method for treating or aiding in the treatment of a tobacco habit or addiction in a human by controlling the craving for tobacco or controlling tobacco withdrawal symptoms which comprises internally administering to said human an effective amount of a compound having an active ingredient containing at least one bivalent negative sulfur to control said craving or said withdrawal symptoms so as to reduce the desire for tobacco.

Abstract: The use of lofexidine and its pharmaceutically acceptable salts in alleviating the adverse symptoms of tobacco withdrawal is disclosed.